Veytics Intelligence
2026-10-14 · NASDAQ

Nxera Pharma Signs Exclusive QUVIVIQ Licensing Deal With Synmosa For Eight Markets

(RTTNews) - Nxera Pharma Co., Ltd. (4565.T), a technology-powered biopharmaceutical company, on Wednesday announced an exclusive licensing, supply and commercialization agreement with Synmosa Biopharma Corp. (4114.TWO).

Leer el informe completo de Veytics

Mostramos la idea principal publicamente. Crea una cuenta gratis para seguir leyendo el articulo completo, guardarlo, comentarlo y conectarlo con contexto de mercados y OSINT.